vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

On February 23, 2025, analysts from StockNews.com initiated coverage of vTv Therapeutics (NASDAQ:VTVT) by issuing a report to investors. In this note, they assigned a "sell" rating to the stock of the biotech firm.

In a separate development, Alliance Global Partners also began covering vTv Therapeutics on December 9, with a more optimistic "buy" rating and a price target set at $35.00.

vTv Therapeutics Stock Performance

The shares of vTv Therapeutics started trading at $20.20 on Friday. The company possesses a market capitalization of $64.44 million. Its price-to-earnings (P/E) ratio stands at -4.46 and the stock shows a beta of 0.73. Over the past year, the stock has experienced a low of $8.10 and a high of $30.99. Currently, the fifty-day moving average is $15.68, while the two-hundred day moving average is $15.09.

Hedge Funds Weigh In On vTv Therapeutics

Recently, several large investors have adjusted their positions in vTv Therapeutics. Notably, FMR LLC acquired a new stake worth $2,402,000 during the third quarter. Additionally, JPMorgan Chase & Co. took on a new position valued at $25,000 during the fourth quarter. Geode Capital Management LLC also increased its stake by 12.9% in the same quarter, now holding 11,634 shares valued at $158,000 after buying an additional 1,327 shares. Currently, institutional investors hold about 17.51% of the company's shares.

About vTv Therapeutics

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to creating orally administered treatments targeting metabolic and inflammatory diseases. The leading candidate in their pipeline is cadisegliatin (TTP399), a liver-selective glucokinase activator, currently undergoing Phase III trials aimed at treating both type 1 and type 2 diabetes. Additionally, TTP273, another candidate which is an orally available small molecule glucagon-like peptide 1 receptor agonist, is in Phase I trials for cystic fibrosis-related diabetes and Phase II trials for type 2 diabetes.

Recommended Stories

• Five stocks we like better than vTv Therapeutics
• What Are Trending Stocks? Trending Stocks Explained
• Unity Stock: Is a True Turnaround Finally Taking Shape?
• Market Cap Calculator: How to Calculate Market Cap
• DuPont’s Electronics Spinoff: The Start of Something Big
• Best Stocks Under $10.00
• The Trade Desk Crashes on Earnings, But Growth Catalysts Persist

Subscribe for Daily News & Ratings - Enter your email below to get a concise daily summary of the latest news and ratings for vTv Therapeutics and related companies.

analysts, stocks, biotechnology